WO2001021178A3 - Method of treating cognitive dysfunction syndrome in dogs and chewable tablet for dogs - Google Patents

Method of treating cognitive dysfunction syndrome in dogs and chewable tablet for dogs Download PDF

Info

Publication number
WO2001021178A3
WO2001021178A3 PCT/US2000/025771 US0025771W WO0121178A3 WO 2001021178 A3 WO2001021178 A3 WO 2001021178A3 US 0025771 W US0025771 W US 0025771W WO 0121178 A3 WO0121178 A3 WO 0121178A3
Authority
WO
WIPO (PCT)
Prior art keywords
dogs
cognitive dysfunction
dysfunction syndrome
treating cognitive
chewable tablet
Prior art date
Application number
PCT/US2000/025771
Other languages
French (fr)
Other versions
WO2001021178A2 (en
Inventor
Elizabeth M Abbott
Susan M Cady
Original Assignee
Akzo Nobel Nv
Elizabeth M Abbott
Susan M Cady
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv, Elizabeth M Abbott, Susan M Cady filed Critical Akzo Nobel Nv
Priority to AU75953/00A priority Critical patent/AU7595300A/en
Publication of WO2001021178A2 publication Critical patent/WO2001021178A2/en
Publication of WO2001021178A3 publication Critical patent/WO2001021178A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods of treating cognitive dysfunction syndrome in dogs. The method includes identifying dogs that have cognitive dysfunction syndrome and administering to them propentofylline. The amount of propentofylline administered to the dogs is an effective amount to treat cognitive dysfunction syndrome. Also described are chewable tablets for dogs containing propentofylline and at least one flavor enhancing ingredient. The tablet may also contain binders, lubricants and/or antioxidants.
PCT/US2000/025771 1999-09-22 2000-09-21 Method of treating cognitive dysfunction syndrome in dogs and chewable tablet for dogs WO2001021178A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU75953/00A AU7595300A (en) 1999-09-22 2000-09-21 Method of treating cognitive dysfunction syndrome in dogs and chewable tablet for dogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40153299A 1999-09-22 1999-09-22
US09/401,532 1999-09-22

Publications (2)

Publication Number Publication Date
WO2001021178A2 WO2001021178A2 (en) 2001-03-29
WO2001021178A3 true WO2001021178A3 (en) 2002-07-11

Family

ID=23588149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025771 WO2001021178A2 (en) 1999-09-22 2000-09-21 Method of treating cognitive dysfunction syndrome in dogs and chewable tablet for dogs

Country Status (2)

Country Link
AU (1) AU7595300A (en)
WO (1) WO2001021178A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2884421B1 (en) 2005-04-15 2007-08-10 Virbac Sa NEW MEANS FOR CONTROLLING BEHAVIORAL DISORDERS IN PETS
US20100152225A1 (en) * 2006-09-20 2010-06-17 David Hung Hydrogenated pyrido [4,3-b] indoles such as dimebon for treating canine cognitive dysfunction syndrome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937076A (en) * 1984-08-10 1990-06-26 Combe Incorporated Chewable aspirin and buffering material tablet and method for producing same
EP0748628A2 (en) * 1995-06-13 1996-12-18 American Home Products Corporation Oral formulations of S(+)-Etodolac
US5780046A (en) * 1995-06-13 1998-07-14 American Home Products Corporation Oral formulations of S(+)-ibuprofen
US5824336A (en) * 1994-05-20 1998-10-20 Janssen Pharmaceutica, N.V. Chewable flubendazole tablets for companion animals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937076A (en) * 1984-08-10 1990-06-26 Combe Incorporated Chewable aspirin and buffering material tablet and method for producing same
US5824336A (en) * 1994-05-20 1998-10-20 Janssen Pharmaceutica, N.V. Chewable flubendazole tablets for companion animals
EP0748628A2 (en) * 1995-06-13 1996-12-18 American Home Products Corporation Oral formulations of S(+)-Etodolac
US5780046A (en) * 1995-06-13 1998-07-14 American Home Products Corporation Oral formulations of S(+)-ibuprofen

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FUJI ET AL.: "Effects of repeated adminisitration of propentofylline on memory impairment produced by basal forebrain lesion in rats", EUR. J. PHARMACOL., vol. 236, no. 3, 4 June 1993 (1993-06-04), pages 411 - 417, XP001034927 *
GOTO ET AL.: "Effects of propentofylline on disorder of learning and memory in rodents", JPN J. PHARMACOL., vol. 45, no. 3, 1987, pages 373 - 378, XP002186238 *
HUDLICKA ET AL.: "The effect of a xanthine derivative, 1-(5'-oxohexyl)-3-methyl-7-propylxanthine (HWA 285), on heart performance and regional blood flow in dogs and rabbits", BRITISH J. PHARMACOL., vol. 72, no. 4, April 1981 (1981-04-01), pages 723 - 730, XP002186247 *
KAPL ET AL.: "Neue pharmakologische Aspekte zum neurologischen Profil von Propentofyllin (Karsivan(R) ad us. evt.)", TIERARZTLICHE PRAXIS, AUSGABE K., KLEINTIERE/HEIMTIERE, vol. 26, no. 5, September 1998 (1998-09-01), pages 317 - 321, XP001035000 *
NOBLE S ET AL: "PROPENTOFYLLINE", CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 8, no. 3, 1997, pages 257 - 264, XP000863567, ISSN: 1172-7047 *
SIWAK ET AL.: "Adrafinil: effects on behavior and cognition in aged canines", PROG. NEURO-PSYCHPHARMACOL. BIOL. PSYCHIATRY, vol. 24, no. 5, 27 July 2000 (2000-07-27), pages 709 - 726, XP001051903 *
STEVENS ET AL.: "Pharmacokinetic studies on HWA 285 in the dog following single oral and intravenous administrations and multiple oral dose administration", JAPANESE PHARMACOL. THER., vol. 144, 1986, pages 25 - 36, XP001034959 *

Also Published As

Publication number Publication date
WO2001021178A2 (en) 2001-03-29
AU7595300A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
BG103575A (en) SUBSTITUTED NITROGENCONTAINING HETEROCYCLES AS p38 PROTEINKINASE INHIBIRORS
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ZA200107315B (en) Pharmaceutical combinations for the treatment of stroke and traumatic brain injury.
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
CA2278422A1 (en) D-methadone, a nonopioid analgesic
WO1999059617A3 (en) Immunoregulator
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
WO1998032428A3 (en) Compositions comprising choline and use of choline to treat endotoxic shock
CA2214531A1 (en) Treatment of cytokine growth factor caused disorders
WO2003015797A8 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
GB9521608D0 (en) Pharmaceutical composition
EA199800866A1 (en) METHOD OF REMOVAL OF PAIN
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
WO2001021178A3 (en) Method of treating cognitive dysfunction syndrome in dogs and chewable tablet for dogs
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
AU562828B2 (en) Morphine-vitamin b12 analgesic treatment
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
HK1046847A1 (en) Pharmaceutical combination with analgesic action containing paracetamol and buspirone.
WO2001034632A3 (en) Aliphatic hydroxy substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents
CA2314865A1 (en) Methods for preventing and treating mastitis
NZ333443A (en) Method of treating a plant disease comprising applying oxi-fulvic acid an acitve ingredient
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
PL328924A1 (en) Method of treating abuse of substances
MX9203208A (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DIGESTIVE DISORDERS.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP